OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
Key Highlights
- ➤Q3 revenue $30.9 million, up 14% year over year
- ➤GAAP gross margin 45.2%, up 170 basis points year over year
- ➤Q4 revenue guidance $30.0 million to $32.0 million
- ➤Diagnostics revenue $16.8 million, up 16% year over year
- ➤Sample Management Solutions revenue $12.5 million, up 21% year over year
Expert Statements
Carrie Eglinton Manner, President and CEO of OraSure Technologies
“Our third quarter results demonstrate the continued execution of our strategy. In addition to delivering double-digit year-over-year revenue growth, we meaningfully expanded gross margins and benefited from operational efficiency initiatives that reduced our cost base”
Carrie Eglinton Manner, President and CEO of OraSure Technologies
“We were excited to see the Q3 commercial launches of both our Colli-Pee•Dx Urine Collection Kit and OraQuick Ebola 2.0 Rapid Antigen Test quickly translate into initial orders during the third quarter. These launches marked significant milestones for OTI as we work to further decentralize diagnostics and connect people to care that is more accessible, convenient, affordable, and private.”
Carrie Eglinton Manner, President and CEO of OraSure Technologies
“Looking ahead to the fourth quarter and into 2027, we believe we are well positioned for continued revenue growth”
Carrie Eglinton Manner, President and CEO of OraSure Technologies
“Supported by a robust balance sheet, we will continue to invest behind initiatives to accelerate topline growth, improve our operating model, and drive towards profitability.”
* 14% year-over-year revenue growth in the quarter highlights effectiveness of return-to-growth strategy * GAAP gross margin improved by over 170 bps vs. prior year to 45.2% * Received initial orders of Colli-Pee®•Dx and OraQuick® Ebola 2.0 in the quarter * OTI expects an acceleration of full-year revenue growth in 2027 BETHLEHEM, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2026.
“Our third quarter results demonstrate the continued execution of our strategy. In addition to delivering double-digit year-over-year revenue growth, we meaningfully expanded gross margins and benefited from operational efficiency initiatives that reduced our cost base,” said Carrie Eglinton Manner, President and CEO of OTI. “We were excited to see the Q3 commercial launches of both our Colli-Pee•Dx Urine Collection Kit and OraQuick Ebola 2.0 Rapid Antigen Test quickly translate into initial orders during the third quarter. These launches marked significant milestones for OTI as we work to further decentralize diagnostics and connect people to care that is more accessible, convenient, affordable, and private.”
Get started
Create a free account to read the full story.